Botulinum strain is not trade secret: U.S. ITC reasons in Daewoong vs Medytox case
이 글자크기로 변경됩니다.
(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.
“The genetic evidence establishes by more than a preponderance of the evidence that Daewoong derived its strain from Medytox,” the ITC said in its entire 74-page opinion released on Wednesday elaborating on the grounds for its December ruling.
“Complainants [however] failed to satisfy their burden to establish that the Medytox strain or its genetic makeup quality as a trade secret.”
The U.S. trade panel on Dec. 16 ordered a 21-month ban on imports of Daewoong Pharmaceutical’s botulinum products into the U.S. – down from the initial 10-year ban proposed by the preliminary panel that said Daewoong Pharmaceutical misappropriated trade secrets that belong to Medytox.
Daewoong Pharmaceutical and Medytox are both manufacturers of botulinum toxin or botox products that are widely used to treat wrinkles.
In 2019, Medytox filed a complaint with the ITC, saying that Daewoong Pharmaceutical stole trade secrets of the manufacturing process and introduced its botox product in the U.S.
Daewoong Pharmaceutical see the latest release has put to an end the long dispute between the two companies over botulinum strain origin.
Daewoong Pharmaceutical still plans to make an appeal with the federal appellate court over the decision that it infringed manufacturing processing technology.
An unnamed official from Daewoong Pharmaceutical said that it has sufficient evidence that it independently developed processing technology of botulinum strain and that Medytox manufacturing process is a generally-used technology from several decades ago and is different from its own.
Medytox expressed regret that the botulinum strain was not taken as trade secret, but still focused on how illegal activity was involved.
The Korea Centers for Disease Control, meanwhile, plans to inspect all local botulinum toxin manufacturers in Korea amid growing controversy over safety and origin of botulinum strain.
[ⓒ Maeil Business Newspaper & mk.co.kr, All rights reserved]
Copyright © 매일경제 & mk.co.kr. 무단 전재, 재배포 및 AI학습 이용 금지
- S. Korea’s SH in talks to partake Russia’s $47 bn urban renewal project - Pulse by Maeil Business News Korea
- Hanwha shares gain traction on rosy outlook for aerospace, solar power biz - Pulse by Maeil Business News Korea
- SK reaps nearly $2 bn in 5 days from investment in Plug Power - Pulse by Maeil Business News Korea
- FTC set to determine punishment on Harim over intra-group trading charge - Pulse by Maeil Business News Korea
- S. Korea’s LS C&S activates its first cable factory in Africa - Pulse by Maeil Business News Korea
- 강경준, 상간남 피소…사랑꾼 이미지 타격 [MK픽] - 스타투데이
- 우버人사이트
- 트와이스 지효 “윤성빈과 열애? 사생활이라 확인 어려워”(공식입장) - MK스포츠
- 이찬원, 이태원 참사에 "노래 못해요" 했다가 봉변 당했다 - 스타투데이
- 양희은·양희경 자매, 오늘(4일) 모친상 - 스타투데이